WeightCare is not available in all 50 states
The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity), a phase 3 study involving 17,604 adults with overweight or obesity and pre-existing CVD but no diabetes, revealed that once-weekly subcutaneous semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% compared with placebo over a mean follow-up of 39.8 months, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke [48]
They regulate your insulin response and regulate your appetite and digestion so you can feel full longer while maximizing nutritional absorption
The most recent reviews are the most relevant, especially given medication storage challenges and evolving FDA regulations
This hormone helps regulate appetite, slow gastric emptying, and improve feelings of fullness, all of which contribute to weight loss